FMP

FMP

Enter

EDSA - Edesa Biotech, Inc.

Financial Statements of Edesa Biotech, Inc.(EDSA), Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializ

photo-url-https://financialmodelingprep.com/image-stock/EDSA.png

Edesa Biotech, Inc.

EDSA

NASDAQ

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

4.38 USD

-0.11 (-2.51%)

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep